Dermata Therapeutics, Inc. (DRMA) stock
DRMANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.57−0.03 (-4.75%)
Close on Nov 17, 2026Market cap $2.29MP/E –Yield –
Dermata Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Dermata Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$8.08M. For fiscal 2025 it was -$7.80M. The highest annual figure on record is -$4.03M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.80M | – |
| FY2024 | Dec 31, 2024 | -$11.16M | – |
| FY2023 | Dec 31, 2023 | -$6.41M | – |
| FY2022 | Dec 31, 2022 | -$8.83M | – |
| FY2021 | Dec 31, 2021 | -$5.69M | – |
| FY2020 | Dec 31, 2020 | -$4.03M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.42M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.48M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.37M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.80M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.69M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.93M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.91M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.42M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.13M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.70M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.15M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.77M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.84M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.65M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.83M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.56M | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.84M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.61M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.80M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.21M | -139.4% |
| Q2 FY2021 | Jun 30, 2021 | -$903.21K | – |
| Q1 FY2021 | Mar 31, 2021 | -$776.22K | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.52M | – |
| Q3 FY2020 | Sep 30, 2020 | $5.62M | – |
See a number that looks wrong?